JP2014034577A5 - - Google Patents

Download PDF

Info

Publication number
JP2014034577A5
JP2014034577A5 JP2013226693A JP2013226693A JP2014034577A5 JP 2014034577 A5 JP2014034577 A5 JP 2014034577A5 JP 2013226693 A JP2013226693 A JP 2013226693A JP 2013226693 A JP2013226693 A JP 2013226693A JP 2014034577 A5 JP2014034577 A5 JP 2014034577A5
Authority
JP
Japan
Prior art keywords
csf
mgd
shows
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013226693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014034577A (ja
JP5815638B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014034577A publication Critical patent/JP2014034577A/ja
Publication of JP2014034577A5 publication Critical patent/JP2014034577A5/ja
Application granted granted Critical
Publication of JP5815638B2 publication Critical patent/JP5815638B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2013226693A 2004-07-22 2013-10-31 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法 Expired - Fee Related JP5815638B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US59056504P 2004-07-22 2004-07-22
US60/590,565 2004-07-22
US64760405P 2005-01-27 2005-01-27
US60/647,604 2005-01-27
US66493205P 2005-03-24 2005-03-24
US60/664,932 2005-03-24
US69901905P 2005-07-14 2005-07-14
US60/699,019 2005-07-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007522769A Division JP5435865B2 (ja) 2004-07-22 2005-07-21 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015029580A Division JP2015133970A (ja) 2004-07-22 2015-02-18 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2014034577A JP2014034577A (ja) 2014-02-24
JP2014034577A5 true JP2014034577A5 (enExample) 2015-04-09
JP5815638B2 JP5815638B2 (ja) 2015-11-17

Family

ID=35448388

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007522769A Expired - Fee Related JP5435865B2 (ja) 2004-07-22 2005-07-21 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2013226693A Expired - Fee Related JP5815638B2 (ja) 2004-07-22 2013-10-31 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2015029580A Pending JP2015133970A (ja) 2004-07-22 2015-02-18 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2016103092A Pending JP2016146850A (ja) 2004-07-22 2016-05-24 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007522769A Expired - Fee Related JP5435865B2 (ja) 2004-07-22 2005-07-21 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015029580A Pending JP2015133970A (ja) 2004-07-22 2015-02-18 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2016103092A Pending JP2016146850A (ja) 2004-07-22 2016-05-24 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Country Status (7)

Country Link
US (4) US20070264277A1 (enExample)
EP (3) EP1778842B8 (enExample)
JP (4) JP5435865B2 (enExample)
AT (1) ATE540973T1 (enExample)
AU (1) AU2005267062C1 (enExample)
CA (1) CA2574654C (enExample)
WO (1) WO2006012451A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
EP1841874B1 (en) * 2005-01-27 2010-01-06 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
US20110212055A1 (en) * 2008-03-25 2011-09-01 Commissiong John W Neurodegenerative disorders
WO2009137631A2 (en) * 2008-05-07 2009-11-12 Wintherix Llc Methods for identifying compounds that affect expression of cancer-related protein isoforms
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
SMT201900074T1 (it) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
US20110312506A1 (en) * 2010-06-17 2011-12-22 Dilyx Biotechnologies, LLC Methods and kits for screening protein solubility
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US20150329639A1 (en) * 2012-12-12 2015-11-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN113046237A (zh) 2014-02-25 2021-06-29 康宁股份有限公司 球状体制造装置、球状体的回收方法及制造方法
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
EP3152557A4 (en) 2014-06-09 2017-12-13 Biometry Inc. Low cost test strip and method to measure analyte
CN113350501A (zh) 2014-06-23 2021-09-07 戊瑞治疗有限公司 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法
US20160060597A1 (en) * 2014-08-28 2016-03-03 The University Of Maryland, Baltimore Functional myelination of neurons
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
JP2017535794A (ja) * 2014-11-03 2017-11-30 バイオインセプト、エルエルシー 免疫調節不全についてのマーカーとしてのｐｉｆ結合
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
AU2017300528C1 (en) 2016-07-19 2022-10-20 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
WO2018133937A1 (en) * 2017-01-19 2018-07-26 Biontech Ag Engineered cells for inducing tolerance
CN107130009A (zh) * 2017-07-13 2017-09-05 华南理工大学 一种具有免疫活性和抗红细胞溶血活性的新型多肽及其制备方法
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
CN109456989B (zh) * 2018-10-31 2022-03-29 陕西慧康生物科技有限责任公司 一种提高毕赤酵母分泌表达的载体的构建方法
CN109593126B (zh) * 2018-11-28 2019-11-22 山西锦波生物医药股份有限公司 多肽、其生产方法和用途
CN109468361B (zh) * 2018-11-29 2021-11-02 电子科技大学 鱼类自然杀伤细胞杀伤细菌感染的单核/巨噬细胞能力的测定方法
CN109596839A (zh) * 2018-12-25 2019-04-09 广州万孚生物技术股份有限公司 人和肽素快速定量检测方法与试剂盒
KR20210121077A (ko) * 2019-01-15 2021-10-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN114113602B (zh) * 2020-08-28 2024-07-02 香港城市大学深圳研究院 免疫球蛋白相关凝血因子x作为急性心肌梗死的生物标志物
US20240335562A1 (en) * 2021-08-04 2024-10-10 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4433092A (en) 1981-03-09 1984-02-21 Champion Spark Plug Company Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5831036A (en) * 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
WO1991002067A1 (en) * 1989-07-27 1991-02-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation of nerve growth factor synthesis in the central nervous system
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5399349A (en) 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
EP0723556A4 (en) 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6395964B1 (en) 1995-10-24 2002-05-28 The Texas A&M University System Oral immunization with transgenic plants
CN1316910A (zh) 1998-02-19 2001-10-10 埃克斯西特治疗公司 用于调节淋巴细胞活化的组合物及方法
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040048249A1 (en) * 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050176927A1 (en) 2000-12-13 2005-08-11 Griffin Jennifer A. Secreted proteins
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2006517094A (ja) * 2002-10-22 2006-07-20 ヌベロ， インコーポレイテッド 新規核酸およびポリペプチド

Similar Documents

Publication Publication Date Title
Jones et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells
Carrega et al. NCR+ ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures
Rochman et al. The role of thymic stromal lymphopoietin in CD8+ T cell homeostasis
Jordan et al. Human interferon lambda-1 (IFN-λ1/IL-29) modulates the Th1/Th2 response
Nagasaka et al. Osteopontin is produced by mast cells and affects IgE‐mediated degranulation and migration of mast cells
Tang et al. The therapeutic effect of ICAM-1-overexpressing mesenchymal stem cells on acute graft-versus-host disease
Gao et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma
Su et al. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species
Joo et al. Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation
Martini et al. Aging induces cardiac mesenchymal stromal cell senescence and promotes endothelial cell fate of the CD90+ subset
Zhou et al. Human umbilical cord-derived mesenchymal stem cells improve learning and memory function in hypoxic-ischemic brain-damaged rats via an IL-8-mediated secretion mechanism rather than differentiation pattern induction
Nakamura et al. Bronchial epithelial cells regulate fibroblast proliferation
Wu et al. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors
Bagheri et al. IL-10 induces TGF-β secretion, TGF-β receptor II upregulation, and IgA secretion in B cells
Fang et al. Skeletal muscle stem cells confer maturing macrophages anti-inflammatory properties through insulin-like growth factor-2
CA3151472A1 (en) Chimeric cytokine receptors
Zhao et al. MAPK phosphatase-1 deficiency exacerbates the severity of imiquimod-induced psoriasiform skin disease
KR101636139B1 (ko) 면역조절능이 우수한 sRAGE 과발현 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
Hajam et al. The expanding impact of T-regs in the skin
Zhang et al. The immunologic properties of undifferentiated and osteogenic differentiated mouse mesenchymal stem cells and its potential application in bone regeneration
Ysebrant de Lendonck et al. STAT3 signaling induces the differentiation of human ICOS+ CD4 T cells helping B lymphocytes
Ma et al. Modulation of liver regeneration via myeloid PTEN deficiency
Evaristo-Mendonça et al. Preconditioning of Rat Bone Marrow‐Derived Mesenchymal Stromal Cells with Toll‐Like Receptor Agonists
Jiang et al. Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model
Malon et al. Involvement of calcitonin gene-related peptide and CCL2 production in CD40-mediated behavioral hypersensitivity in a model of neuropathic pain